Veronica Diermayr, PhD, on AI-Driven Prediction of N256-Glycosylated CEACAM5/6 Expression in Gastric and Esophageal Cancer
ASCO 2026
Veronica Diermayr, PhD, of EDDC and A*STAR, discusses the use of artificial intelligence (AI) driven strategy called H&E 2.0 in gastric and esophageal cancer. Researchers tested the feasibility of training deep-learning models on hematoxylin and eosin images of gastroesophageal carcinomas and their ability to predict EBC-129 antigen expression directly from these images. EBC-129 is an experimental antibody-drug conjugate that targets N256-glycosylated CEACAM5/6, which is highly expressed on solid tumors, including gastroesophageal cancers (Abstract 4018).
Laura Alder, MD, of Duke University Medical Center, highlights emerging data discussed in the meeting’s oral abstract session on small cell lung cancer, including increased toxicity without efficacy benefit from concurrent chemoradiation and immunotherapy, the intracranial activity of tarlatamab-dlle, and early data for a SEZ6-targeting antibody-drug conjugate.
The ASCO Post Staff
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses safety results for DESTINY-Gastric03 Part 2 (arms D and F) and Part 4. The trial evaluated first-line fam-trastuzumab deruxtecan-nxki–based regimens in advanced HER2-expressing gastric cancer, gastroesophageal adenocarcinoma, and esophageal carcinoma (Abstract 4002).
The ASCO Post Staff
Alicia K. Morgans, MD, FASCO, of Dana-Farber Cancer Institute, discusses data from the phase II ARACOG (AFT-47) randomized clinical trial, which compared the two androgen receptor pathway inhibitors’ effects on cognitive function in patients with advanced prostate cancer (Abstract 5005).
The ASCO Post Staff
Peter Schmid, MD, PhD, FRCP, of Queen Mary University of London, shares more data from the phase III lidERA BC clinical trial. This analysis focused on the efficacy and safety of giredestrant in patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer, looking at both premenopausal and postmenopausal populations (Abstract 502).
The ASCO Post Staff
Manali Kamdar, MD, of the University of Colorado, discusses a rapid oral abstract session that highlighted three trends in the field of lymphomas: improving outcomes in frontline diffuse large B-cell lymphoma, continued development of cellular therapies, and expanding molecular profiling.
